The U.S. government has awarded Kernal Bio and three other sub-awardees up to $48 million to help advance the biotech’s in vivo mRNA-encoded CAR T-cell program. In an interesting—if not somewhat ...
Moderna (MRNA) has drawn attention after its stock climbed around 12% over the past week. Investors are weighing the company’s recent financial results, as annual revenue shows about 20% growth and ...
Given the labyrinth of patent litigation ongoing between companies that were working on mRNA vaccines during the pandemic, a merger agreement between two of them – BioNTech and CureVac – raised ...
Findings published in Nature Biomedical Engineering and presented at ESMO 2025 validate iOncologi's Universal Immune Fortifying RNAs (UNIFYRs™) as a new class of RNA therapeutics poised to transform ...
13:23 EDT Moderna (MRNA) down 4.2% after publishing results on mRNA-4359 plus pembrolizumab Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback